An American researcher has said that taking certain anti-inflammatories can improve the health of people who have had skin cancer.
The study was published in the Journal of the American Academy of Dermatology, and it was conducted by Dr. David F. Shaver, a professor of dermatology at the University of Arizona in Tucson.
He and his team examined data from the Mayo Clinic Skin Cancer Registry, which is a registry of more than 5 million patients, and found that taking the NSAIDs, taken at various times, in combination with some sun protection techniques helped to reduce the incidence of melanoma.
The Mayo Clinic is one of the largest providers of prescription drugs for skin cancer and the leading source of prescription drug information in the United States.
The researchers looked at skin cancer in people between the ages of 45 and 80, as well as people of other races and ethnicities.
The data shows that those who were taking NSAIDs at least five days a week were 25 percent less likely to develop melanoma compared with those who had taken them less frequently, Shaver said.
People who took NSAIDs more often also showed a reduction in their melanoma rates compared with people who took them less often.
Shaver said that people with advanced melanoma often needed a large number of treatments to treat their disease.
Shavers study also found that some patients who had had melanoma were less likely than others to benefit from NSAIDs treatment.
In addition to being an effective treatment, NSAIDs are also known to be effective at reducing the growth of other cancers.
The team also found evidence that the combination of NSAIDs and sun protection had a positive impact on melanoma cell growth.
Melanoma cells can grow in the skin when sunlight hits them and produce a protein called tyrosinase, which breaks down the proteins melanin and its associated pigments.
Tyrosinases are involved in the production of many other proteins, including proteins involved in cell growth and differentiation.
The authors of the study said that their findings are the first to show that NSAIDs may improve melanoma treatment and could be useful for people at high risk for the disease.
“We are now looking to explore the safety of this combination, as there are no long-term studies on the safety and efficacy of NSAIDS in people at higher risk for melanoma,” Shaver told ABC News.
“The idea is to get people with melanoma and other skin cancers to start taking NSAIDS as early as possible and continue using them over time.”